Cipla Technologies, a subsidiary of Cipla and Pulmatrix Inc., a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced signing a definitive agreement for the co-development and commercialization of Pulmazole.